The 5‐year survival rate for patients with GC showing TM4SF1 positive was 58.82% (10/17), and the median survival time was 78 months, higher than that (12.90%, 12/93) of patients with GC showing TM4SF1 negative whose median survival time was 62 months. This evidence concerns the gene TM4SF1 and gastric cancer.